Actively Recruiting
Safety Study of Fycompa Injection in People with Partial-Onset or Primary Generalized Tonic-Clonic Seizures
Led by Eisai Co., Ltd. · Updated on 2026-07-01
110
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the safety of Fycompa injection in individuals with epilepsy, specifically those experiencing partial-onset seizures including secondarily generalized seizures aged 4 years or older, or primary generalized tonic-clonic seizures aged 12 years or older. The study is observational and noninterventional, focusing on monitoring safety in a real-world clinical setting. Participants in this study will not receive any additional intervention as the study observes those who have been prescribed Fycompa for injection for the first time in routine clinical care. The study involves no experimental treatment assignment or placebo groups. Participants will be monitored for up to 4 weeks to record any adverse drug reactions and adverse events. Safety assessments include measuring plasma concentrations of Fycompa in children aged 4 to less than 12 years. The study tracks outcomes based on participant characteristics and collects data during usual care without additional procedures.
CONDITIONS
Brief Title
A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures
Research Team
E
Eisai Inquiry Service
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here